


# A high number of losses in 13q14 chromosome is associated with a worse outcome and biological differences in patients with B chronic lymphoid leukemia (B-CLL)

José-Ángel Hernández,<sup>1</sup> Ana-Eugenia Rodríguez,<sup>2</sup> Marcos González,<sup>3</sup> Rocío Benito,<sup>2</sup> Celia Fontanillo,<sup>2</sup> Virgilio Sandoval,<sup>4</sup> Mercedes Romero,<sup>5</sup> Guillermo Martín-Núñez,<sup>6</sup> Alfonso García de Coca,<sup>7</sup> Rosa Fisac,<sup>8</sup> Josefina Galende,<sup>9</sup> Isabel Recio,<sup>10</sup> Francisco Ortuño,<sup>11</sup> Juan-Luis García,<sup>2</sup> Javier de las Rivas,<sup>2</sup> Norma-Carmen Gutiérrez,<sup>2,3</sup> Jesús-Fernando San Miguel,<sup>2,3</sup> and Jesús-María Hernández<sup>2,3</sup>

<sup>1</sup>Servicios de Hematología, Hospital Infanta Leonor, Madrid; <sup>2</sup>IBMCC, Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC; <sup>3</sup>Hospital Clínico Universitario de Salamanca; <sup>4</sup>Hospital Virgen Blanca, León; <sup>5</sup>Hospital del Río Hortega, Valladolid; <sup>6</sup>Hospital Virgen del Puerto, Plasencia, Cáceres; <sup>7</sup>Hospital Clínico Universitario, Valladolid; <sup>8</sup>Hospital General de Segovia; <sup>9</sup>Hospital del Bierzo, León; <sup>10</sup>Hospital Nuestra Señora de Sonsoles, Ávila, an <sup>11</sup>Hospital Morales Meseguer, Murcia, Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL), Unidad de Investigación, Hospital Universitario de Salamanca, Spain

Citation: Hernández J-A, Rodríguez A-E, González M, Benito R, Fontanillo C, Sandoval V, Romero M, Martín-Núñez G, de Coca AG, Fisac R, Galende J, Recio I, Ortuño F, García J-L, de las Rivas J, Gutiérrez N-C, San Miguel J-F, and Hernández J-M. A high number of losses in 13q14 chromosome is associated with a worse outcome and biological differences in patients with B chronic lymphoid leukemia (B-CLL). *Haematologica* 2009; doi:10.3324/haematol.13862



**Online Supplementary Figure S1.** Overall survival (Figure 1sa) and time to first therapy (Figure 1sb) of patients with B-CLL and 13q14 deletion as the sole aberration and a percentage of FISH losses < 50 %, 51-79 % or  $\geq$  80 %.